

Appl. No. 10/710,778

Amdt. dated April 29, 2007

Reply to Office action of November 29, 2006

REMARKS/ARGUMENTS

In response to the most recent Office action, the claims are now amended to overcome the objections indicated therein by the examiner. Claim 12 is amended to remove the superfluous period at the end of the recitation “single entities or mixtures” in part (a). Claims 12-20 are currently amended to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 12-20 now correctly refer to independent claim 11 on which they depend.

Claims 11- 20 were rejected under 35 U.S.C. 112 first paragraph, as failing to comply with the written description requirement, since claims 12-20 recited ranges that were not described in the original specification. These claims are now amended to recite ranges or amounts that are found in the specification.

Claim 12 is now amended to recite that the orally administered composition contains about 400 mg of boswellic acid. 400 mg is the amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], in the specification.

Claim 13 is now amended to recite that the orally administered composition contains about 100 micrograms of selenium. 100 micrograms of selenium is the amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], in the specification.

Claim 14 is now amended to recite that the topically applied composition contains about 400 mg of boswellic acid. 400 mg is the amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], in the specification.

Claim 15 is now amended to recite that the orally administered composition contains about 400 mg of acetyl-11-keto-beta-boswellic acid. 400 mg is the amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], in the specification.

Claim 16 is now amended to recite that the orally administered composition contains about 100 microgram of selenium from L(+) Selenomethionine. 100 microgram

is the amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], in the specification.

Claim 17 is now amended to recite that the topically administered composition contains about 400 mg of acetyl-11-boswellic acid. 400 mg boswellic acid is the amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], in the specification.


Claim 18 is now amended to recite that the total orally administered daily dose of boswellic acids is about 1200 mg. This value is derived from the 400 mg boswellic acids amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], the dose regimen being administered thrice daily, as mentioned in paragraph [0065] in the specification.

Claim 19 is now amended to recite that the total orally administered daily dose of selenium is about 300 micrograms. This value is derived from the 100 micrograms of selenium amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], the dose regimen being administered thrice daily, as mentioned in paragraph [0065] in the specification.

Claim 20 is now amended to recite that the total topically administered daily dose of boswellic acids is about 1200 mg. This value is derived from the 400 mg boswellic acids amount mentioned in the exemplary embodiment of the invention in Example 2, paragraph [0064], the dose regimen being administered thrice daily, as mentioned in paragraph [0065] in the specification.

As this response is being submitted after the expiration of the shortened statutory period for response specified in the Office Action, applicants respectfully request that an extension of time of two months be granted, for which the required extension fee is submitted herewith. Applicants respectfully request that this amendment be entered and that a timely Notice of Allowance be issued in this case.

Respectfully submitted,
SABINSA CORPORATION



Dr. Subbalakshmi Prakash
VP Innovation & Business Development
Registration No: 57192
Tel: (732) 777 1111